GCA
SRPT icon

Gideon Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Gideon Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,580
Closed -$849K – 188
2019
Q4 		$849K Buy
6,580
+2,647
+67% +$267K 0.29% 127
2019
Q3 		$296K Buy
+3,933
New +$464K 0.1% 233

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Gideon Capital Advisors's SRPT Position: Q1 2020 in Review

Gideon Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2020, closing a stake of 6,580 shares — an estimated $849K sold.

Gideon Capital Advisors first reported a position in SRPT in Q3 2019 and held it in 2 quarters. The position peaked at $849K in Q4 2019. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2020.

  • Gideon Capital Advisors reported no remaining Sarepta Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Gideon Capital Advisors sold 6,580 Sarepta Therapeutics shares in Q1 2020, an estimated $849K.
  • Gideon Capital Advisors first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 2 quarters.
  • Gideon Capital Advisors's Sarepta Therapeutics position peaked at $849K in Q4 2019.
  • 366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2020.

Based on Gideon Capital Advisors's 13F filing for Q1 2020.